Velaglucerase alfa, a human recombinant glucocerebrosidase enzyme replacement therapy for type 1 Gaucher disease

Current Opinion in Investigational Drugs

Volumn 11, Issue 4, 2010, Pages 472-478

  Pastores, Gregory M ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMIGLUCERASE; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

ARTHRALGIA; BACKACHE; BONE PAIN; CLINICAL TRIAL; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG WITHDRAWAL; ENZYME REPLACEMENT; ENZYME SYNTHESIS; FEVER; GAUCHER DISEASE; HUMAN; INFLUENZA; LARYNX PAIN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; NOSE CONGESTION; PARTIAL THROMBOPLASTIN TIME; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; UPPER ABDOMINAL PAIN; VOMITING;

ENZYME REPLACEMENT THERAPY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDES; HUMANS; MACROPHAGES;

EID: 77950118269     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. Phase I/II, nine month study results of enzyme replacement therapy with gene activated human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease. Zimran A, Fratazzi C, Mensah R, Elstein D BLOOD 2005 106 11 Abs 3882
2. Superior effects of high-dose enzyme replacement therapy in type 1 Gaucher disease on bone marrow involvement and chitotriosidase levels: A 2-center retrospective analysis. de Fost M, Hollak CEM, Greener JEM, Aerts JMFG, Maas M, Poll LW, Wiersma MG, Haussinger D, Brett S, Brill N, vom Dahl S BLOOD 2006 108 3 830-835
3. Phase I/II, 9-month study results of enzyme replacement therapy with gene-activated human glucocerebrosidase in patients with type 1 Gaucher disease. Zimran A, Fratazzi C, Altarescu G, Mensah R, Elstein D ACTA PAEDIATR 2007 96 Suppl 455 106
4. Phase I/II study of glucocerebrosidase replacement therapy in patients with type I Gaucher disease. Zimran A, Elstein D, Loveday K, Aliski W, Fratazzi C ACTA PAEDIATR 2006 95 Suppl 451 143
5. months on treatment: Open-label phase I/II long-term study of enzyme replacement therapy (ERT) with "gene-activated" human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease. Zimran A, Bhirangi K, Mensah R, Altarescu G, Elstein D MOL GENET METAB 2008 93 2 Abs 118
6. NCT00891202: A study of Genz-112638 in patients with Gaucher disease. Genzyme CLINICALTRIALS.GOV 2009
7. A pharmacokinetic analysis of a novel enzyme replacement therapy with gene-activated human glucocerebrosidase (GA-GCB) in patients with type 1 Gaucher disease. Zimran A, Loveday K, Fratazzi C, Elstein D BLOOD CELLS MOL DIS 2007 39 1 115-118
8. 24-months on treatment: Open-label phase I/II long-term study of enzyme replacement therapy (ERT) with gene-activated human glucocerebrosidase (GA-GCB) in patients with type I Gaucher disease. Zimran A, Altarescu G, Fratazzi C, Mensah R, Elstein D MOL GENET METAB 2007 92 4 Abs 22
9. Supply shortages of Cerezyme and Fabrazyme - Priority access for patients most in need of treatment recommended. European Agency for the Evaluation of Medicinal Products PRESS RELEASE 2009 June 25
10. Shire completes submission of NDA for velaglucerase alfa for type 1 Gaucher disease and reports positive results for remaining two phase III trials. Shire plc PRESS RELEASE 2009 September 01
11. Shire plc Q3 2009 earnings call. Shire plc COMPANY PRESENTATION 2009 November 01
12. Shire submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the treatment of Type 1 Gaucher disease. Shire plc PRESS RELEASE 2009 November 24
13. Pfizer and Protalix enter into agreement to develop and commercialize Gaucher's disease treatment. Pfizer Inc PRESS RELEASE 2009 December 01
14. Genzyme begins shipping newly produced Cerezyme from Allston plant. Genzyme Corp Press Release 2009 December 01
15. Characterization of gene-activated human acid- β-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS, Futerman AH GLYCOBIOLOGY 2010 20 1 24-32
16. Gaucher disease: New developments in treatment and etiology. Harmanci O, Bayraktar Y WORLD J GASTROENTEROL 2008 14 25 3968-3973
17. Replacement therapy for inherited enzyme deficiency - Macrophage-targeted glucocerebrosidase for Gaucher's disease. Barton NW, Brady RO, Dambrosia JM, Dibisceglie AM, Doppelt SH, Hill SC, Mankin HJ, Murray GJ, Parker RI, Argoff CE, Grewal RP et al N ENGL J MED 1991 324 21 1464-1470
18. Enzyme therapy in type 1 Gaucher disease: Comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, Mckee MA, Parker C, Schiffmann R, Hill SC, Brady RO ANN INTERN MED 1995 122 1 33-39
19. Goal-oriented therapy with miglustat in Gaucher disease. Pastores GM, Giraldo P, Cherin P, Mehta A CURR MED RES OPIN 2009 25 1 23-37
20. Metabolic adaptations to interrupted glycosaminoglycan recycling. Woloszynek JC, Kovacs A, Ohlemiller KK, Roberts M, Sands MS J BIOL CHEM 2009 284 43 29684-29691
21. Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system. Shaaltiel Y, Bartfeld D, Hashmueli S, Baum G, Brill-Almon E, Galili G, Dym O, Boldin-Adamsky SA, Silman I, Sussman JL, Futerman AH et al PLANT BIOTECHNOL J 2007 5 5 579-590
22. Recombinant glucocerebrosidase (imiglucerase) as a therapy for Gaucher disease. Pastores GM BIODRUGS 2010 24 1 41-47
23. Five-year safety and efficacy of velaglucerase alfa in Gaucher disease type 1: Experience in clinic and home settings. Elstein D, Zimran A, Cohn GM, Bhirangi K LYSOSOMAL DIS NETWORK: WORLD ANN SYMP 2010 6 February 12 Abs 49
24. Enzyme replacement therapy with velaglucerase alfa significantly improves key clinical parameters in type 1 Gaucher disease: Positive results from a randomized, double-blind, global, phase III study. Zimran A, Gonzalez D, Lukina EA, Ben Dridi M-F, Kisinovsky I, Crombez E, Bhirangi K LYSOSOMAL DIS NETWORK: WORLD ANN SYMP 2010 6 February 12 Abs 157
25. Enzyme replacement therapy with velaglucerase alfa improves key clinical parameters in a pediatric subgroup with type 1 Gaucher disease. Zimran A, Gonzalez D, Crombez E, Bhirangi K LYSOSOMAL DIS NETWORK: WORLD ANN SYMP 2010 6 February 12 Abs 156
26. Antigenic differences in patients receiving velaglucerase alfa or imiglucerase treatment. Ruiz J, Barzegar S, Clarke A, Durant J, Milhaven J, Nadeau M, Nguyen T, Oommen S, Pan L, Rabinovich D, Rickenbach B et al LYSOSOMAL DIS NETWORK: WORLD ANN SYMP 2010 6 February 12 Abs 123
27. Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1. Grabowski GA, Kacena K, Cole JA, Hollak CEM, Zhang L, Yee J, Mistry PK, Zimran A, Charrow J, vom Dahl S GENET MED 2009 11 2 92-100
28. Dosing enzyme replacement therapy for Gaucher disease: Older, but are we wiser? Sidransky E, Pastores GM, Mori M GENET MED 2009 11 2 90-91
29. Shire presents positive efficacy and safety data for velaglucerase alfa in treatment of naïve patients with type 1 Gaucher disease. Shire plc PRESS RELEASE 2010 February 11
30. Excellent results in a transformational year for Shire; Core product sales up 25%. Shire plc PRESS RELEASE 2010 February 19
31. Shire announces FDA approval of VPRIV (velaglucerase alfa for injection) for the treatment of type 1 Gaucher disease. Shire plc Press Release 2010 February 26